Satsuma Pharmaceuticals Files for $80 Million IPO

Satsuma Pharmaceuticals file the paperwork for an $80 million IPO on 9/11/19. The company is developing a nasal delivery form of dihydroergotamine mesylate (DHE) for treating migraine headaches. Satsuma will trade on NASDAQ under the symbol “STSA.”